AZA group (n=43) CYC group (n=72)
p
Female, n (%) 39 (90.7) 57(77.9) 0.126
Age 59.4±14.5 53.8±14.5 0.037
Smoking history, n (%) 6 (14) 15 (20.8) 0.629
CTD disease duration (median) 6 (1-16) 6 (1-12) 0.719
Concomitant steroid usage** 17 (39.5) 26 (36) 0.722
CTD subtype n (%) SSc RA pSS IMS IPAF Other 5(10.6) 8 (50) 7(43.8) 9 (65) 13 (65) 1 (50) 42(89.4) 8(50) 9 (56.3) 5(35) 7 (35) 1 (50)
<0.001
csDMARD usage n (%) bDMARD usage n (%) 25(58 ) 1 (2) 45 (62.5) 2 (2.5) 0.771 0.902
ILD pattern on HRCT, n (%) NSIP n (%) SSc RA pSS IMS IPAF UIP n (%) SSc RA pSS IMS IPAF 30(69.8) 4 (9.5) 3 (50) 5 (45.5) 8 (61) 10 (66.7) 12(27.9) 1 (20) 5 (50) 2 (40 ) 1 (100) 3 (60) 57 (79) 38 (90.5) 3 (50) 6 (54.5) 5 (38.5) 5 (33.3) 14(19.4) 4 (80) 5 (50) 3 (60) - 2 (40) 0.563 [2]0.552
Percentage of lung reticulation on HRCT, median (IQR) 30 (5-55 ) 30 (10-20) 0.901
Extent of Lung Involvement (limited group %) 16(37.2%) 15(20.8%) 0.081
MMRC*, (median) 2 (0-4) 2 (1-3) 0.427
DLCO (%)*(median) 58 (41-75) 59 (40-78) 0.630
FVC, liter* 2.33(1.37- 3.29) 2.19 (1.13-3.25 ) 0.689
FVC, predicted % (median) 83 (55-111) 72 (61-83) 0.032
GAP score 1 (0-2) 1 (0-2) 0.33